Free study: a randomised, open label, multicentre strategic study to evaluate the efficacy and toxicity of an early switch from a PI-containing regimen [lamivudine/zidovudine + lopinavir/ritonavir] to Trizivir [lamivudine/zidovudine/abacavir] on guidance of viral load in HIV-1 infected , antiretroviral naïve adults.

Trial Profile

Free study: a randomised, open label, multicentre strategic study to evaluate the efficacy and toxicity of an early switch from a PI-containing regimen [lamivudine/zidovudine + lopinavir/ritonavir] to Trizivir [lamivudine/zidovudine/abacavir] on guidance of viral load in HIV-1 infected , antiretroviral naïve adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Lamivudine/zidovudine; Lamivudine/zidovudine/abacavir; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms FREE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 May 2010 Actual patient numbers amended from 320 to 207 as reported by ClinicalTrials.gov.
    • 26 May 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top